Search results
CAR-T Plus Stem-Cell Transplant Promising for CD7+ Blood Cancers
MedPage Today· 20 hours agoA strategy of sequential CD7 chimeric antigen receptor (CAR) T-cell therapy and haploidentical...
HanxBio announces the publication of a research paper in Scientific Reports on preclinical...
FOX 4 Kansas City· 2 days agoHanxBio today announced that it has published a research article titled "Narazaciclib, a novel...
Deverra Therapeutics Granted FDA Fast Track Designation for DVX101
Digital Journal· 4 hours agoDesignation Validates Preliminary Data and Supports Accelerated Drug Development SEATTLE, WA / ACCESSWIRE / April 24, 2024 / Deverra Therapeutics, Inc., a clinical-stage biotechnology company ...
Potential new treatment strategy for aggressive leukemia
Medical Xpress· 6 days agoIn findings published in Nature Cancer, researchers reveal that blocking these oxygen-sensing enzymes can significantly halt acute myeloid leukemia ...
...Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute ...
Morningstar· 7 days ago“We are delighted to safely progress through the second, higher dose cohort to reach an important study milestone for the United States Food and Drug Administration...
Moleculin's acute myeloid leukemia treatment gets EMA's orphan drug designation
Seeking Alpha· 6 days agoMoleculin Biotech's Annamycin receives Orphan Drug Designation from the European Medicines Agency for AML treatment, expanding its potential market reach.
FDA grants breakthrough status for Kura Oncology's AML drug candicate By Investing.com
Investing.com· 3 days agoFood and Drug Administration (FDA) has awarded Breakthrough Therapy Designation to its drug...
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute ...
NBC 17 Raleigh· 7 days ago– Next-generation non-cardiotoxic anthracycline Annamycin with notable signs of clinical efficacy in AML in combination with Cytarabine achieves preliminary CRc rate of 60% in 2nd line AML subjects ...
Bio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study
Zacks via Yahoo Finance· 5 days agoBio-Path (BPTH) gains 30% on encouraging developmental updates from the early-stage study of its...
Tiger Aesthetics Medical, LLC Acquires Assets of Sientra, Inc.
Digital Journal· 3 hours agoVienna ball season back in full swing ‘Avatar 2’ success proves cinema in post-pandemic ‘resurgence’: Cameron North of ...